Moreover, the 36-month beta value for CDTX is 0.89. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CDTX is 6.84M and currently, short sellers hold a 4.24% of that float. On April 02, 2025, CDTX’s average trading volume was 124.43K shares.
CDTX) stock’s latest price update
The stock price of Cidara Therapeutics Inc (NASDAQ: CDTX) has dropped by -12.16 compared to previous close of 21.54. Despite this, the company has seen a fall of -14.12% in its stock price over the last five trading days. globenewswire.com reported 2025-04-01 that SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
CDTX’s Market Performance
Cidara Therapeutics Inc (CDTX) has experienced a -14.12% fall in stock performance for the past week, with a -17.92% drop in the past month, and a -20.14% drop in the past quarter. The volatility ratio for the week is 9.68%, and the volatility levels for the past 30 days are at 7.86% for CDTX. The simple moving average for the past 20 days is -15.12% for CDTX’s stock, with a 14.90% simple moving average for the past 200 days.
Analysts’ Opinion of CDTX
Many brokerage firms have already submitted their reports for CDTX stocks, with Citizens JMP repeating the rating for CDTX by listing it as a “Mkt Outperform.” The predicted price for CDTX in the upcoming period, according to Citizens JMP is $46 based on the research report published on March 12, 2025 of the current year 2025.
RBC Capital Mkts gave a rating of “Outperform” to CDTX, setting the target price at $34 in the report published on December 13th of the previous year.
CDTX Trading at -13.18% from the 50-Day Moving Average
After a stumble in the market that brought CDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.43% of loss for the given period.
Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 9.68%, as shares sank -18.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.81% lower at present.
During the last 5 trading sessions, CDTX fell by -14.12%, which changed the moving average for the period of 200-days by +31.66% in comparison to the 20-day moving average, which settled at $22.29. In addition, Cidara Therapeutics Inc saw -29.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDTX starting from Ward Shane, who sale 1,664 shares at the price of $21.96 back on Mar 11 ’25. After this action, Ward Shane now owns 14,674 shares of Cidara Therapeutics Inc, valued at $36,542 using the latest closing price.
Tari Leslie, the CHIEF SCIENTIFIC OFFICER of Cidara Therapeutics Inc, sale 1,773 shares at $21.96 during a trade that took place back on Mar 11 ’25, which means that Tari Leslie is holding 16,215 shares at $38,940 based on the most recent closing price.
Stock Fundamentals for CDTX
Current profitability levels for the company are sitting at:
- -10.65 for the present operating margin
- 0.82 for the gross margin
The net margin for Cidara Therapeutics Inc stands at -19.12. The total capital return value is set at -0.57. Equity return is now at value -222.36, with -121.39 for asset returns.
Based on Cidara Therapeutics Inc (CDTX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -49.37.
Currently, EBITDA for the company is -176.1 million with net debt to EBITDA at 2.01. When we switch over and look at the enterprise to sales, we see a ratio of 2.39. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.25.
Conclusion
To wrap up, the performance of Cidara Therapeutics Inc (CDTX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
